Avadel Pharmaceuticals-adr (AVDL)
$18.09
+1.09
(+6.41%)▲
Performance
- $16.52$18.82$18.09
8.68%
Downside
Day's Volatility :12.2%
Upside
3.85%
- $9.50$18.09$18.09
47.48%
Downside
52 Weeks Volatility :47.48%
Upside
0.0%
Returns
| Period | Avadel Pharmaceuticals-adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 14.25% | -0.8% | 0.0% |
6 Months | 49.12% | 5.7% | 0.0% |
1 Year | 68.65% | 3.0% | -0.7% |
3 Years | 142.51% | 14.1% | -21.8% |
Highlights
Market Capitalization | 1.5B |
Book Value | $0.98 |
Earnings Per Share (EPS) | -2.0 |
PEG Ratio | 0.07 |
Wall Street Target Price | 22.9 |
Profit Margin | 0.0% |
Operating Margin TTM | -128.0% |
Return On Assets TTM | -57.92% |
Return On Equity TTM | -481.35% |
Revenue TTM | 28.0M |
Revenue Per Share TTM | 0.35 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 16.6M |
EBITDA | -136.1M |
Diluted Eps TTM | -2.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.4 |
EPS Estimate Next Year | 1.02 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.22 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 26.59%
Technicals Summary
Sell
Neutral
Buy
Avadel Pharmaceuticals-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Avadel Pharmaceuticals-adr | 7.8% | 49.12% | 68.65% | 142.51% | 142.51% |
 Neurocrine Biosciences Inc. | -5.52% | 15.97% | 26.53% | 36.41% | 55.52% |
 Haleon Plc Spon Ads | -0.74% | -2.3% | -7.14% | 8.77% | 8.77% |
 Zoetis Inc. | -12.26% | -14.51% | -14.23% | -10.65% | 51.02% |
 Viatris Inc. | -3.74% | 19.54% | 14.23% | -15.52% | -30.72% |
 Catalent, Inc. | 0.21% | 20.55% | 23.44% | -49.29% | 31.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals-adr | NA | NA | 0.07 | -0.4 | -4.81 | -0.58 | NA | 0.98 |
Neurocrine Biosciences Inc. | 54.74 | 54.74 | 0.44 | 4.69 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.61 | 28.61 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.58 | 29.58 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 231.9 | 231.9 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.45 | -0.3 | -0.01 | NA | 20.41 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Avadel Pharmaceuticals-adr | Buy | $1.5B | 142.51% | NA | 0.0% |
Neurocrine Biosciences Inc. | Buy | $13.5B | 55.52% | 54.74 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 8.77% | 28.61 | 9.28% |
Zoetis Inc. | Buy | $68.5B | 51.02% | 29.58 | 27.43% |
Viatris Inc. | Hold | $13.8B | -30.72% | 231.9 | 0.35% |
Catalent, Inc. | Hold | $10.2B | 31.77% | 211.02 | -31.77% |
Institutional Holdings
HHG PLC
12.28%RTW INVESTMENTS, LLC
7.67%Polar Capital Holdings PLC
7.45%Gendell Jeffrey L
6.20%Vivo Capital, LLC
4.52%WEALTH EFFECTS LLC
2.67%
Corporate Announcements
Avadel Pharmaceuticals-adr Earnings
Avadel Pharmaceuticals-adr’s price-to-earnings ratio stands at None
Read More
Company Information
avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.
Organization | Avadel Pharmaceuticals-adr |
Employees | 154 |
CEO | Mr. Gregory J. Divis Jr. |
Industry | Health Technology |
